{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:57:59Z","timestamp":1794542279148,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Adverse event (AE) collection is a key part of evidence generation in clinical trials and an integral element of safety reporting. AE assessment and documentation is particularly challenging in neonates who are a heterogeneous population with high rates of co-morbidities. Neonatal research is finally gaining the attention of regulators regarding drug development and the need for optimal dosing specific to this population. However, further efforts are necessary to ensure that adverse events (AEs) are adequately collected, allowing for the generation of essential safety data. It is also crucial that the methodology used aligns with the intended trial outcomes to minimise the burden on trial sites. In resource-constrained settings, where pharmacovigilance implementation can be particularly challenging, a pragmatic approach to safety reporting is even more important given the significant public health need for effective drugs. This commentary reflects on some of the challenges and potential areas of improvement in safety reporting that could be addressed in future neonatal-focused trials.<\/jats:p>","DOI":"10.1186\/s13063-025-08723-y","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T19:13:08Z","timestamp":1739128388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety reporting in neonatal clinical trials: reflections towards optimal, globally relevant approaches"],"prefix":"10.1186","volume":"26","author":[{"given":"Louise F.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina W.","family":"Obiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrie","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Bielicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-9581","authenticated-orcid":false,"given":"Francesca","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"8723_CR1","unstructured":"European Medicines Agency. Guideline for Good Clinical Practice E6(R2) [Internet]. London; 2016 Dec. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf"},{"key":"8723_CR2","doi-asserted-by":"publisher","first-page":"1345969","DOI":"10.3389\/fped.2023.1345969","volume":"11","author":"CHT Yeung","year":"2023","unstructured":"Yeung CHT, Verstegen RHJ, Greenberg R, Lewis TR. Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials. Front Pediatr. 2023;11:1345969.","journal-title":"Front Pediatr"},{"key":"8723_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-017-0850-x","volume":"78","author":"P Pansa","year":"2018","unstructured":"Pansa P, Hsia Y, Bielicki J, Lutsar I, Walker AS, Sharland M, et al. Evaluating safety reporting in paediatric antibiotic trials, 2000\u20132016: A systematic review and meta-analysis. Drugs. 2018;78:231\u201344.","journal-title":"Drugs"},{"key":"8723_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/IDR.S287792","volume":"14","author":"IA Dutescu","year":"2021","unstructured":"Dutescu IA, Hillie SA. Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study. Infect Drug Resist. 2021;14:415\u201334.","journal-title":"Infect Drug Resist"},{"key":"8723_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41372-021-01304-2","volume":"42","author":"T Lewis","year":"2022","unstructured":"Lewis T, Wade KC, Davis JM. Challenges and opportunities for improving access to approved neonatal drugs and devices. J Perinatol. 2022;42:825\u20138.","journal-title":"J Perinatol"},{"key":"8723_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bcp.13883","volume":"85","author":"C Ollivier","year":"2019","unstructured":"Ollivier C, Thomson A, Manolis E, Blake K, Karlsson KE, Knibbe CAJ, et al. Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics. Br J Clin Pharmacol. 2019;85:659\u201368.","journal-title":"Br J Clin Pharmacol"},{"key":"8723_CR7","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S1473-3099(16)00069-4","volume":"16","author":"L Folgori","year":"2016","unstructured":"Folgori L, Bielicki J, Ruiz B, Turner MA, Bradley JS, Benjamin DK, et al. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis. 2016;16:e178\u201389.","journal-title":"Lancet Infect Dis"},{"key":"8723_CR8","doi-asserted-by":"crossref","unstructured":"Allegaert K, Ward RM, Van Den Anker JN. Neonatal pharmacology. Avery\u2019s Diseases of the Newborn. 11th ed. Philadelphia: Elsevier; 2023. p. 253\u201365.","DOI":"10.1016\/B978-0-323-82823-9.00021-0"},{"key":"8723_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bcp.12467","volume":"79","author":"MA Turner","year":"2015","unstructured":"Turner MA. Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct. Br J Clin Pharmacol. 2015;79:370\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"8723_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/INF.0000000000002433","volume":"38","author":"C Jackson","year":"2019","unstructured":"Jackson C, Hsia Y, Basmaci R, Bielicki J, Heath PT, Versporten A, et al. Global divergence from World Health Organization treatment guidelines for neonatal and pediatric sepsis. Pediatric Infectious Disease Journal. 2019;38:1104\u20136.","journal-title":"Pediatric Infectious Disease Journal"},{"key":"8723_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204427","volume":"13","author":"HTM De Lima Costa","year":"2018","unstructured":"De Lima Costa HTM, Costa TX, Martins RR, Oliveira AG. Use of off-label and unlicensed medicines in neonatal intensive care. PLoS ONE. 2018;13: e0204427.","journal-title":"PLoS ONE"},{"key":"8723_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s13312-014-0468-y","volume":"51","author":"S Jain","year":"2014","unstructured":"Jain S, Saini SS, Chawla D, Kumar P, Dhir S. Off-label use of drugs in neonatal intensive care units. Indian Pediatr. 2014;51:644\u20136.","journal-title":"Indian Pediatr"},{"key":"8723_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1753-2000-2-38","volume":"2","author":"P Auby","year":"2008","unstructured":"Auby P. Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective. Child Adolesc Psychiatry Ment Health. 2008;2:38.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"8723_CR14","unstructured":"European Medicines Agency. Better medicines for children. London; 2015. Available from:\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/better-medicines-children_en.pdf"},{"key":"8723_CR15","unstructured":"Food & Drug Administration. Best Pharmaceuticals for Children Act and Pediatric Research Equity Act Status Report to Congress. Maryland; 2020."},{"key":"8723_CR16","unstructured":"World Health Organization. 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva; 2024. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/376944\/9789240094000-eng.pdf?sequence=1"},{"key":"8723_CR17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11096-017-0570-z","volume":"40","author":"S Elshafie","year":"2018","unstructured":"Elshafie S, Zaghloul I, Roberti AM. Pharmacovigilance in developing countries (part I): importance and challenges. Int J Clin Pharm. 2018;40:758\u201363.","journal-title":"Int J Clin Pharm"},{"key":"8723_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14740338.2021.1991307","volume":"20","author":"N Vargesson","year":"2021","unstructured":"Vargesson N, Stephens T. Thalidomide: history, withdrawal, renaissance, and safety concerns. Expert Opin Drug Saf. 2021;20:1455\u20137.","journal-title":"Expert Opin Drug Saf"},{"key":"8723_CR19","first-page":"205","volume":"2","author":"CD Furberg","year":"2001","unstructured":"Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205\u20137.","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"8723_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/tropicalmed7050064","volume":"7","author":"F Rosa-Mangeret","year":"2022","unstructured":"Rosa-Mangeret F, Benski AC, Golaz A, Zala PZ, Kyokan M, Wagner N, et al. 2.5 million annual deaths\u2014are neonates in low- and middle-income countries too small to be seen? A bottom-up overview on neonatal morbi-mortality. Trop Med Infect Dis. 2022;7:64.","journal-title":"Trop Med Infect Dis"},{"key":"8723_CR21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s11096-017-0588-2","volume":"40","author":"S Elshafie","year":"2018","unstructured":"Elshafie S, Roberti AM, Zaghloul I. Pharmacovigilance in developing countries (part II): a path forward. Int J Clin Pharm. 2018;40:764\u20138.","journal-title":"Int J Clin Pharm"},{"key":"8723_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/archdischild-2019-317399","volume":"104","author":"T Salaets","year":"2019","unstructured":"Salaets T, Turner MA, Short M, Ward RM, Hokuto I, Ariagno RL, et al. Development of a neonatal adverse event severity scale through a Delphi consensus approach. Arch Dis Child. 2019;104:1167\u201373.","journal-title":"Arch Dis Child"},{"key":"8723_CR23","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1038\/s41372-021-01164-w","volume":"41","author":"T Lewis","year":"2021","unstructured":"Lewis T, Terrin N, Davis J, Michels K, Salaets T, Wade K. Inter-rater reliability of the neonatal adverse event severity scale using real-world neonatal clinical trial data. J Perinatol. 2021;41:2813\u20139.","journal-title":"J Perinatol"},{"key":"8723_CR24","unstructured":"Developmental Outcomes of Long-term Supplementation in Neonates - the DOLFIN randomised controlled trial protocol. 2023. Available from: https:\/\/www.npeu.ox.ac.uk\/assets\/downloads\/dolfin\/DOLFIN_Protocol_V40_021023.pdf"},{"key":"8723_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.siny.2006.02.007","volume":"11","author":"RE Grunau","year":"2006","unstructured":"Grunau RE, Holsti L, Peters JWB. Long-term consequences of pain in human neonates. Semin Fetal Neonatal Med. 2006;11:268\u201375.","journal-title":"Semin Fetal Neonatal Med"},{"key":"8723_CR26","unstructured":"IMPAACT: Pharmacokinetic characteristics of antiretrovirals and tuberculosis medicine in low birth weight infants protocol. 2018.\u00a0Available from: https:\/\/www.impaactnetwork.org\/studies\/p1106. [cited 2024 Oct 13]."},{"key":"8723_CR27","doi-asserted-by":"publisher","unstructured":"ISRCTN 48721236. NeoSep1: a study to determine the ranking of existing and new antibiotics combinations to treat newborn babies who are in hospital with severe sepsis. cited 2023 Sep 12. Available from: 2022. https:\/\/doi.org\/10.1186\/ISRCTN48721236.","DOI":"10.1186\/ISRCTN48721236"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08723-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08723-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08723-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T19:13:13Z","timestamp":1739128393000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08723-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8723"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08723-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}